Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Bladder Cancer
jRCT2041250006Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of Erda-iDRS in bladder cancer, non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events (AEs) (Parts 1 to 3), Number of Participants with AEs by Severity (Parts 1 to 3) and 2 more. Started Aug 2025; status: active, not recruiting.
02
Drugs
Erda-iDRS
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on jRCT2041250006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250006.